Skip to content

Issue 11-08-2010

Walgreens said to be eyeing sale of PBM

Published reports late last month said Walgreen Co. is looking to sell its pharmacy benefit management (PBM) business and has hired an adviser to run an auction. Citing people with knowledge of the matter, several news agencies said the drug chain has hired Bank of America Corp.

Jaeger becomes CEO of NCPA

The National Community Pharmacists Association (NCPA) has turned to a trade association veteran with a proven track record to lead it into the future.

Kerr Drug sees another approach to pharmacy

While national drug chains are successful at what they do, there is another approach to pharmacy, says Kerr Drug president and chief executive Tony Civello. That approach is exemplified by Kerr’s forward-looking Community Healthcare Center in Chapel Hill, N.C.

Importance of Rx adherence recognized

The National Association of Chain Drug Stores has hailed an article in the Journal of the American Medical Association (JAMA) as further validation of the need for public policy to embrace pharmacists’ expertise in helping patients take their medications correctly.

Walgreens, Epocrates join forces

The Walgreens Prescription Savings Club (PSC), a formulary of more than 8,000 branded and generic medications, is now accessible to doctors and other prescribing health care providers through a partnership between Walgreen Co. and Epocrates Inc.

Supervalu chain purchases six Rinderer’s stores

Super­valu Inc.’s Shop ’n Save food and drug chain has acquired Rinderer’s Drug Stores Inc. The deal for the six-store drug chain will see Shop ’n Save incorporate three Rinderer’s units into its store base, bringing its total number of community pharmacies in the St. Louis and Springfield, Ill.

Retail merchants who understand the game

In the mass retailing firmament, the retailer is king. For industry suppliers, a primary objective is getting close to the retail merchants who make the key decisions affecting their products. There’s no new news in the previous paragraph.

R&D may be casualty as Rx makers retrench

If a new survey of pharmaceutical executives whose companies account for more than 40% of the industry’s global revenue is any indication, an era characterized by a remarkable level of innovation may be drawing to a close.